Philippines - English - FDA (Food And Drug Administration)

sanofi pasteur inc - yellow fever vaccine - powder for suspension im/sc multidose - 1000 units / 0.5ml

Israel - English - Ministry of Health

sanofi israel ltd - levofloxacin as hemihydrate - film coated tablets - levofloxacin as hemihydrate 500 mg - levofloxacin - levofloxacin - tavanic tablets 500 mg is indicated in adults for the treatment of the following infections:- acute pyelonephritis and complicated urinary tract infections - chronic bacterial prostatitisin the below-mentioned infections, tavanic should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.- acute bacterial sinusitis - acute exacerbations of chronic obstructive pulmonary disease including bronchitis - community-acquired pneumonia- complicated skin and soft tissue infections.tavanic may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - purified tetanus toxoid - suspension, sterile - 40 i.u. / 0.5ml dose - purified tetanus toxoid 40 i.u. / 0.5ml dose

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - purified tetanus toxoid - suspension, sterile - ≥ 40 i.u. / 0.5ml dose - purified tetanus toxoid ≥ 40 i.u. / 0.5ml dose

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - hepatitis a virus (inactivated) - injection - 160 u/0.5 ml - hepatitis a virus (inactivated) 160 u/0.5 ml

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - hepatitis a virus (inactivated) - injection, suspension - 80 antigen units - hepatitis a virus (inactivated) 80 antigen units

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - human poliovirus type 3 inactivated; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; diphtheria toxoid; haemophilus influenzae type b polysaccharide protein conjugate - suspension for injection

Israel - English - Ministry of Health

sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:- active immunisation of adults, including pregnant women, and children from 6 months of age and older- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women.the use of vaxigrip tetra should be based on official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - immunoglobulin - rabies -

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - haemophilus influenzae type b, conjugate with tetanus protein - pdr+solv for soln for inj - 10mcg/0.5m microgram/ml - hemophilus influenzae b vaccines